Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEOBiotechnology
-$0.05 today
- Market cap
- $244.23M
- Beta
- 1.39
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.08
Volume 1.76M
Average 0.86M
LXEO Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Lexeo Therapeutics, Inc. Common StockNASDAQ: LXEO
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $21.79M fell 35.6% year over year, behind the -16.4% change in trailing-twelve-month operating expenses. Sequentially, it fell 5.7% from the prior quarter. Over 3 fiscal years it compounded at +21.3% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -35.6% toward the trailing-twelve-month pace of -16.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 109.26M USD
- Year-over-year change
- +3.3%
- 4-year CAGR
- +20.2%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 109.26M | +3.3% |
| FY2024 | 2024-12-31 | 105.77M | +54.4% |
| FY2023 | 2023-12-31 | 68.51M | +12.0% |
| FY2022 | 2022-12-31 | 61.16M | +17.0% |
| FY2021 | 2021-12-31 | 52.29M | — |
Operating Expenses vs competitors
How LXEO compares with its peers on the latest reported figures
- LXEO's LTM Mar 2026 operating expenses of $97.24M is the 6th highest of the 11 companies compared; the peer median is $122.96M.
- Its year-over-year change of -16.4% is the 9th highest of 10, against a peer median of +44.9%.
- Over three fiscal years its annual growth of +21.3% compares with a peer median of +30.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $361.73M | +36.9% | +16.5% | 166.1% | |
| LTM Mar 2026 | $172.43M | +63.7% | +67.8% | — | |
| LTM Mar 2026 | $164.05M | +44.9% | +13.2% | — | |
| LTM Mar 2026 | $162.92M | +24.9% | +67.1% | — | |
| LTM Mar 2026 | $150.13M | -11.1% | -27.1% | 69.9% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $97.24M | -16.4% | +21.3% | — |
| LTM Mar 2026 | $95.79M | +126.8% | +68.5% | 262.5% | |
| LTM Mar 2026 | $87.2M | — | +16.9% | 9463.1% | |
| LTM Mar 2026 | $77.53M | +359.8% | +118.0% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $66.77M | +256.3% | +44.2% | — |
| LTM Mar 2026 | $37.72M | -21.8% | -10.5% | 7543.6% | |
| Peer median (excluding LXEO) | $122.96M | +44.9% | +30.5% | 262.5% | |
Competitors are the stored peer set for LXEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.66M | 654K | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.66M | 654K | 0 | 0 | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 45.12M | 49.16M | 53.13M | 74.09M | 63.8M |
| Selling, General & Admin | 7.17M | 12M | 15.38M | 31.68M | 45.46M |
| Operating Expenses | 52.29M | 61.16M | 68.51M | 105.77M | 109.26M |
| Depreciation & Amortization | 13K | 1.15M | 1.84M | 2M | 2.08M |
| EBITDA | (50.61M) | (58.04M) | (64.35M) | (96.19M) | (97.68M) |
| EBITDA Margin | -3054.3% | -8874.8% | — | — | — |
| Operating Income | (50.64M) | (60.51M) | (68.51M) | (105.77M) | (109.26M) |
| Operating Margin | -3055.9% | -9252.1% | — | — | — |
| Interest Income | 15K | 1.33M | 2.87M | 7.56M | 6.13M |
| Interest Expense | 0 | 91K | 205K | 114K | 206K |
| Other Income / Expenses | 15K | 1.23M | 2.12M | 7.43M | 9.3M |
| Income Before Tax | (50.62M) | (59.28M) | (66.39M) | (98.33M) | (99.96M) |
| Pre-Tax Margin | -3055.0% | -9063.8% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.62M) | (59.28M) | (66.39M) | (98.33M) | (99.96M) |
| Net Margin | -3055.0% | -9063.8% | — | — | — |
| EPS (Basic) | (2.01) | (2.36) | (2.49) | (3.09) | (1.86) |
| EPS (Diluted) | (2.01) | (2.40) | (2.49) | (3.09) | (1.86) |
| Weighted Avg Shares | 25.17M | 25.17M | 26.65M | 31.79M | 53.65M |
| Weighted Avg Shares (Diluted) | 25.17M | 25.17M | 26.65M | 31.79M | 53.65M |
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
Intrinsic Alpha fair value
Locked
Current Price
$2.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.